Suchergebnisse - "van de Donk, Niels W C J"

PubPharm (19)

1

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

CommentIn: N Engl J Med. 2024 Apr 18;390(15):1440. - PMID 38631009

2

Management of multiple myeloma-related renal impairment : recommendations from the International Myeloma Working Group

enthalten in: The Lancet. Oncology | 2023

von Dimopoulos, M. | Merlini, G. | Bridoux, F. | +25

3

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma

enthalten in: Advances in therapy | 2023

von Moreau, P. | van de Donk, N. | Delforge, M. | +19

4

Corticosteroid tapering is a safe approach in patients with relapsed or refractory multiple myeloma receiving subcutaneous daratumumab : part 3 of the open-label, multicenter, phase 1b PAVO study

enthalten in: Leukemia & lymphoma | 2023

von Nahi, H. | Usmani, S. | Mateos, M. | +10

5

Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001) : a multicentre, multicohort, open-label, phase 1/2 trial

enthalten in: The Lancet. Haematology | 2022

von Lonial, S. | Popat, R. | Hulin, C. | +18

CommentIn: Lancet Haematol. 2022 Nov;9(11):e799-e801. - PMID 36209763

6

LocoMMotion : a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

enthalten in: Leukemia | 2022

von Mateos, M. | Weisel, K. | De Stefano, V. | +30

7

Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Sonneveld, P. | Dimopoulos, M. | Beksac, M. | +37

8

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Moreau, P. | Hulin, C. | Perrot, A. | +49

CommentIn: Nat Rev Clin Oncol. 2021 Nov;18(11):676. - PMID 34545220

9

Ixazomib, Daratumumab, and Low-Dose Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma : The Hovon 143 Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2021

von Stege, C. | Nasserinejad, K. | van der Spek, E. | +22

10

Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study

enthalten in: Haematologica | 2021

von Hulin, C. | Offner, F. | Moreau, P. | +20